Xenon Pharmaceuticals Inc. Advances in 2025 with Promising Phase 3 Developments in Epilepsy and Psychiatry
Xenon Pharmaceuticals Inc. is making progress in 2025 with promising developments in its clinical-stage endeavors, including advancements in Phase 3 programs for epilepsy and psychiatry.
2 minutes to read